EBIDTA before CSR and Impact of Ind AS 116 was at Rs 511 million
Metropolis Healthcare announced its un-audited financial results for the quarter ended June 30, 2019. The company registered consolidated revenue growth of 15.7 per cent at Rs 2033 million backed by robust volume growth.
The company posted a growth in the total number of patients which was at 17.7 per cent, the growth in number of tests performed was 20.9 per cent, the growth in revenue per test was 5.5 per cent as compared to full year FY18-19 and growth in revenue per patient was 5.3 per cent as compared to full year FY18-19.
EBIDTA before CSR and Impact of Ind AS 116 was at Rs 511 million, 25.15 per cent on revenue (15.4 per cent growth). Accounting EBIDTA was at Rs 550 million, 27.07 per cent on revenue (24.2 per cent growth). PAT before CSR and exceptional items and Impact of Ind AS 116 was at Rs 350 million, 17.2 per cent on revenue (28.3 per cent growth).
Commenting on the annual results, Ameera Shah, MD, Metropolis Healthcare said, “We are happy to announce our first quarter results for FY20. Q1 is typically a lean quarter for the industry but we have witnessed a healthy revenue and volume growth. Keeping in line with our growth strategy, we are witnessing an increase in revenue contribution from our retail business, reflecting patient trust and preference for Metropolis. Strong operating parameters gives us comfort that we are moving in the right direction.”